Join NETRF’s ‘Research Changes Lives’ Giving Tuesday Campaign—Every gift doubled now through December 3, 2024. LEARN MORE
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Research is at the very core of what we do at NETRF. We believe it is the key to discovering cures and more effective treatments for neuroendocrine cancers. In this episode of NETWise, we share some of the most important developments in NET research that happened in 2023, and look back on the progress made in the past year. Lastly, we’ll look ahead to new developments on the horizon.
Dawn E. Quelle, PhD., is co- chair of NETRF’s Board of Scientific Advisors. She is a professor of Neuroscience and Pharmacology and leader of the Cancer Genes and Pathways Program at Holden Comprehensive Cancer Center at the University of Iowa Carver College of Medicine.
Pamela L. Kunz, MD is an associate professor of Internal Medicine, director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, Chief, GI Medical Oncology and Vice Chief, Diversity, Equity, and Inclusion for Medical Oncology.
Anna Greene, PhD., is NETRF’s director of research
Email questions or feedback to podcast@netrf.org. Find us on Facebook and Twitter, YouTube.
Sign up to have NETRF notify you of the next NETWise podcast. Or, find and subscribe to NETWise on your favorite podcast service.
Medical Disclaimer: This podcast is not intended as and shall not be relied upon as medical advice. The Neuroendocrine Tumor Research Foundation encourages all users to discuss any information found here with their oncologist, physician, and/or appropriate qualified health professional. Listening to this podcast does not constitute a patient-physician relationship. The Neuroendocrine Tumor Research Foundation does not represent that any information provided here should supplant the reasoned, informed advice of a patient’s oncologist, physician, or appropriate qualified health professional.